Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Royalty Pharma Plc (RPRX)  
$28.41 0.35 (1.22%) as of 4:30 Fri 5/3


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 365,900,000
Market Cap: 10.40(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $26.21 - $35.52
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Royalty Pharma is a buyer of biopharmaceutical royalties. The royalties in Co.'s marketed portfolio related to approved products include: cystic fibrosis franchise, which consists of Co.'s right to receive royalty payments on the sale of various products for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor); and Tysabri, which is a monoclonal antibody for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 600,000 600,000
Total Buy Value $0 $0 $19,310,880 $19,310,880
Total People Bought 0 0 1 1
Total Buy Transactions 0 0 6 6
Total Shares Sold 0 1,470,000 3,562,221 9,145,341
Total Sell Value $0 $41,892,742 $110,436,570 $343,351,745
Total People Sold 0 2 4 11
Total Sell Transactions 0 9 17 76
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 252
  Page 8 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Engelbert Catherine M. Director   –       •      –    2021-06-25 4 A $0.00 $0 D/D 5,726 19,136     -
   Lloyd George W. EVP, Investments & GC   •       –      –    2021-06-10 4 S $46.45 $3,254,369 I/I (70,000) 240,000 21%     
   Lloyd George W. EVP, Investments & GC   •       –      –    2021-06-08 4 S $46.47 $3,253,631 I/I (70,000) 250,000 20%     
   Reddoch James F. EVP, Research & Investments   •       –      –    2021-06-08 4 AS $46.43 $2,321,540 I/I (50,000) 1,270,800 -20%     
   Lloyd George W. EVP, Investments & GC   •       –      –    2021-06-07 4 S $45.89 $5,676,228 I/I (122,500) 260,000 23%     
   Riggs Rory B Director   –       •      –    2021-06-07 4 S $45.26 $12,385,399 I/I (273,650) 2,081,540 23%     
   Reddoch James F. EVP, Research & Investments   •       –      –    2021-06-07 4 AS $46.57 $2,329,419 I/I (50,000) 1,320,800 -23%     
   Urist Marshall EVP & Co-Head of R&I   •       –      –    2021-06-07 4 S $47.02 $779,059 D/D (16,568) 0 23%     
   Lloyd George W. EVP, Investments & GC   •       –      –    2021-06-04 4 S $44.69 $2,686,938 I/I (60,000) 280,000 20%     
   Reddoch James F. EVP, Research & Investments   •       –      –    2021-06-04 4 AS $44.60 $4,459,730 I/I (100,000) 1,370,800 -20%     
   Urist Marshall EVP & Co-Head of R&I   •       –      –    2021-06-04 4 S $45.13 $747,662 D/D (16,566) 16,568 20%     
   Reddoch James F. EVP, Research & Investments   •       –      –    2021-06-02 4 S $42.13 $2,106,560 I/I (50,000) 1,470,800 17%     
   Urist Marshall EVP & Co-Head Research & Inv.   •       –      –    2021-06-02 4 S $41.52 $604,850 D/D (14,566) 33,134 17%     
   Lloyd George W. EVP, Investments & GC   •       –      –    2021-06-02 4 S $42.09 $2,632,513 I/I (62,500) 1,050,000 17%     
   Urist Marshall EVP & Co-Head Research & Inv.   •       –      –    2021-05-21 4 S $41.00 $4,100 D/D (100) 47,700 11%     
   Urist Marshall EVP & Co-Head Research & Inv.   •       –      –    2021-05-20 4 S $41.08 $78,059 D/D (1,900) 47,800 10%     
   Reddoch James F. EVP, Research & Investments   •       –      –    2021-05-07 4 A $0.00 $0 I/I 1,320,800 1,520,800     -
   Coyne Terrance P. EVP & CFO   •       –      –    2021-05-07 4 A $0.00 $0 I/I 1,000,000 1,000,000     -
   Legorreta Pablo G. CEO, Chairman of the Board   •       •      –    2021-05-07 4 A $0.00 $0 I/I 2,325,000 1,284,590     -
   Riggs Rory B Director   –       •      –    2021-05-07 4 A $0.00 $0 I/I 2,355,190 2,355,190     -
   Riggs Rory B Director   –       •      –    2021-05-07 4 A $0.00 $0 D/D 679,760 679,760     -
   Lloyd George W. EVP, Investments & GC   •       –      –    2021-05-07 4 A $0.00 $0 I/I 1,875,860 300,000     -
   Urist Marshall EVP & Co-Head Research & Inv.   •       –      –    2021-05-07 4 A $0.00 $0 D/D 49,700 49,700     -
   Reddoch James F. EVP, Research & Investments   •       –      –    2021-04-14 4 S $42.10 $2,345,593 I/I (55,714) 200,000 8%     
   Lloyd George W. EVP, Investments & GC   •       –      –    2021-04-14 4 S $42.12 $2,941,920 I/I (69,822) 200,000 8%     
  252 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us